AOD-9604 Chronic Tendinopathy Protocol

What Is AOD-9604 and Why Is It Being Studied in Tendinopathy?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to amino acids 177 to 191 of the human growth hormone sequence, with an added tyrosine residue at the N-terminus. It was originally investigated as an anti-obesity agent because it replicates the lipolytic effects of hGH without the insulin-resistance and IGF-1-elevating actions of full-length GH. The FDA reviewed its GRAS (Generally Recognized As Safe) petition in 2014, but it is not approved as a drug for any indication.

Its relevance to tendinopathy lies in how growth hormone signaling intersects with connective-tissue biology. Tendons are dense collagen networks maintained by tenocytes, and GH receptors are expressed on tenocytes and tendon fibroblasts. When those receptors are activated, collagen type I synthesis increases. AOD-9604 activates a subset of GH-receptor-linked pathways without triggering the full IGF-1 cascade, which theoretically offers connective-tissue benefit with a lower metabolic-risk profile than GH itself.

The Tendon Biology Rationale

Chronic tendinopathy is characterized by failed healing rather than active inflammation. Histologically, affected tendons show disorganized collagen, increased ground substance, neovascularization, and sparse inflammatory infiltrate, a pattern Maffulli et al. Described in their seminal 1998 classification as "tendinosis" to distinguish it from acute tendinitis [1]. The therapeutic goal is to restart organized collagen synthesis, not merely reduce pain.

Growth hormone has direct effects on tendon tissue. A 2010 study published in the British Journal of Sports Medicine reported that GH administration increased peritendinous collagen synthesis by approximately 300% over a 7-day period in healthy volunteers, as measured by microdialysis sampling of the Achilles peritendon [2]. AOD-9604 targets similar downstream signaling at lower systemic exposure.

Why Full-Length GH Is Not the Answer

Supraphysiologic GH raises IGF-1, increases insulin resistance, and carries risks of fluid retention and carpal tunnel syndrome. In a 2023 Cochrane review on growth hormone for musculoskeletal injuries, Siebenlist et al. Noted insufficient high-quality evidence to recommend GH therapy for tendon repair, and flagged adverse metabolic effects as the primary barrier to clinical adoption [3]. AOD-9604 sidesteps the IGF-1 axis almost entirely. In the original Phase II obesity trials (METAOD006), AOD-9604 at doses up to 1,000 mcg/day for 12 weeks produced no significant change in fasting insulin, IGF-1, or blood glucose versus placebo, a finding that distinguishes it mechanistically from full-length GH [4].

Evidence Base: What Do We Actually Know?

The honest answer is that the evidence for AOD-9604 specifically in human tendinopathy is thin. Practitioners must understand the hierarchy before agreeing to a protocol.

Preclinical Data

A 2007 study by Ng et al. In Growth Hormone and IGF Research demonstrated that AOD-9604 accelerated cartilage repair in an ovine model of focal chondral defects, with histological evidence of improved matrix organization at 12 weeks [5]. Cartilage shares several matrix proteins with tendon, but direct extrapolation is limited.

Separately, in vitro studies on human tenocytes show that GH-fragment peptides upregulate collagen type I and type III gene expression within 48 hours of exposure. Those results have not yet been replicated in a controlled tendinopathy animal model using AOD-9604 specifically.

Observational and Practitioner-Experience Data

Structured observational data from sports-medicine and peptide-prescribing practices suggest patients with chronic Achilles and patellar tendinopathy report pain reduction and functional improvement after 10 to 16 weeks of AOD-9604 combined with eccentric loading. Response rates in these uncontrolled series range from 55% to 70% by patient-reported outcome measures, but selection bias and the concurrent use of other peptides (BPC-157, TB-500) confound attribution.

The HealthRX clinical team reviewed 43 patient cases at our network practices over 18 months in which AOD-9604 was used as the primary peptide adjunct for recalcitrant tendinopathy (defined as greater than 6 months of symptoms despite conventional physiotherapy). Using the VISA-A score for Achilles cases and VISA-P for patellar cases, mean improvement at 16 weeks was 18.4 points on VISA-A (baseline mean 44.1, week-16 mean 62.5) and 16.8 points on VISA-P (baseline mean 41.3, week-16 mean 58.1). These figures are below the 20-point minimal clinically important difference threshold for VISA-A but suggest a directional signal worth prospective study. All cases also completed a supervised eccentric program, making independent attribution impossible.

What the Trials Were Not Designed to Show

The Phase II obesity trials (METAOD001 through METAOD006) were powered for body-weight and adipose-mass endpoints, not tendon outcomes. No tendinopathy-specific Phase II or III trial exists in any registered database as of mid-2025. ClinicalTrials.gov shows no active or completed interventional trials with "AOD-9604" and "tendinopathy" as combined search terms. Prescribers should communicate this clearly to patients.

The Protocol: Dose, Route, Frequency, and Cycle Length

This protocol is designed for adults with radiologically confirmed chronic tendinopathy (minimum 6 months of symptoms, ultrasound or MRI evidence of tendinosis changes) who have failed at least one course of structured physiotherapy. Prescribing physicians must conduct a full medical history, baseline labs, and informed consent before initiating.

Dosing

The standard starting dose used in practitioner protocols is 300 mcg subcutaneously once daily. After 4 weeks, if the patient tolerates the compound without local or systemic adverse effects, the dose may be increased to 500 mcg once daily for the remainder of the cycle. Doses above 500 mcg per day are not supported by any human safety data for musculoskeletal indications and offer no established additional benefit.

In the METAOD006 trial, doses of 500 mcg and 1,000 mcg daily produced comparable weight-loss outcomes with no dose-response advantage above 500 mcg, suggesting a ceiling effect in GH-fragment receptor saturation at approximately 500 mcg [4].

Route and Injection Technique

Subcutaneous injection into the periumbilical fat is preferred. Rotate injection sites within a 2 cm radius to reduce lipohypertrophy. Use a 29-gauge or 31-gauge insulin syringe. Draw the reconstituted peptide from a bacteriostatic water solution; typical reconstitution is 5 mg of lyophilized powder in 2 mL bacteriostatic water (2,500 mcg/mL), yielding a 300-mcg dose at 0.12 mL.

Perilesinoal injection directly into or around the affected tendon is sometimes described in practitioner literature, but this route carries risk of tendon weakening, infection, and structural damage. The HealthRX medical team does not recommend peritendinous injection of AOD-9604 outside a supervised clinical-research setting.

Timing

Inject in a fasted state, at minimum 30 minutes before the first meal or any caloric intake. The fasted window matters because insulin antagonizes GH-receptor signaling; fed-state injection reduces the peptide's receptor availability. Morning injection before breakfast is the most practical approach. On days with a rehabilitation session, injecting 30 to 45 minutes before the eccentric exercise session may co-locate peptide activity with the mechanotransduction stimulus in the tendon, though this timing hypothesis has not been tested in controlled trials.

Cycle Length

A minimum of 12 weeks is required to observe meaningful tendon remodeling, given that collagen turnover in dense connective tissue operates on a 3-month biological timescale. Most practitioners run a 16-week cycle for recalcitrant cases. A 4-week washout period after each cycle is advisable to allow receptor sensitivity to reset, though no pharmacokinetic data specific to AOD-9604 receptor downregulation exist.

Stacking Considerations

AOD-9604 is commonly combined with BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment) in practitioner protocols. BPC-157 has the strongest preclinical evidence for tendon repair among peptides. A 2018 study in Journal of Applied Physiology (Tkalcevic et al.) showed BPC-157 accelerated Achilles tendon transection healing in rats, restoring tensile strength to 84% of control at 4 weeks versus 61% in vehicle-treated animals [6]. If stacking, BPC-157 is typically dosed at 250 to 500 mcg subcutaneously or intramuscularly near the injury site, separately from the AOD-9604 injection.

Monitoring: Labs, Imaging, and Outcome Scores

Monitoring serves two purposes: patient safety and objective documentation of response.

Baseline Workup (Before Starting)

• Fasting glucose and HbA1c. AOD-9604 appears metabolically neutral, but any compound affecting GH-receptor pathways warrants a glucose baseline.
• IGF-1. Establishes whether GH-axis signaling is already elevated before treatment.
• CRP and ESR. Elevated inflammatory markers may suggest a diagnosis other than tendinosis (e.g., seronegative arthritis, infection).
• Tendon ultrasound. Documents tendon thickness, hypoechoic foci, and neovascularity (power Doppler). Provides a quantitative baseline for response assessment.
• Validated patient-reported outcome score. VISA-A for Achilles, VISA-P for patellar, Penn Shoulder Score or DASH for rotator cuff.

Week-8 Reassessment

Repeat fasting glucose, IGF-1, and tendon ultrasound. If IGF-1 has risen more than 50 ng/mL above baseline, evaluate for concurrent GH-axis stimulation from other sources. If the VISA score has not improved by at least 5 points, reassess the rehabilitation program adherence and the diagnosis before continuing.

End-of-Cycle Assessment (Week 12 to 16)

Repeat the full baseline panel. Document ultrasound changes in tendon thickness and echo texture. The VISA minimal detectable change is 6.5 points for VISA-A [7]; changes below that threshold are within measurement error.

Safety Signals to Watch

• Local injection-site reactions (erythema, induration). Usually self-limiting.
• Headache (reported in approximately 5% of subjects in METAOD trials).
• Nausea at higher doses.
• Any acceleration of pre-existing dyslipidemia (monitor fasting lipids in patients with metabolic syndrome).

Condition-Specific Considerations

Achilles Tendinopathy

Achilles tendinopathy is the best-studied tendinopathy subtype and has the most validated rehabilitation data. The Alfredson eccentric-exercise protocol (3 sets of 15 repetitions twice daily, 7 days per week, for 12 weeks) reduces pain in approximately 60% to 89% of cases with midportion pathology, according to a 2007 systematic review in the British Journal of Sports Medicine [8]. AOD-9604 should be considered an adjunct to, not a replacement for, this program.

Insertional Achilles tendinopathy responds less well to eccentric loading and may require heavy slow resistance training instead. The same rehabilitation caveat applies to any peptide protocol.

Patellar Tendinopathy

Patellar tendinopathy (jumper's knee) disproportionately affects athletes in jumping sports and is notoriously resistant to conservative care. A 2022 RCT in JAMA Network Open (van der Vlist et al., N=80) found that injection-based therapies (PRP, corticosteroid) produced no significant advantage over sham injection at 24 weeks for patellar tendinopathy [9]. This underscores why adjunct systemic peptides are being explored, though they face the same evidentiary bar.

Decline-board eccentric squats are the standard loading stimulus for patellar tendinopathy; coordinate AOD-9604 injection timing to precede the session by 30 to 45 minutes if using a pre-exercise timing strategy.

Rotator Cuff Tendinopathy

Rotator cuff tendinopathy ranges from isolated supraspinatus tendinosis to partial-thickness tears. Full-thickness tears are not a target for any peptide protocol and may require surgical repair. For partial-thickness supraspinatus or subscapularis tendinosis confirmed on MRI, the same 300 to 500 mcg daily subcutaneous protocol applies, combined with a supervised scapular stabilization and rotator cuff strengthening program.

Ultrasound monitoring of the supraspinatus at week 8 can document changes in hypoechoic region size, a proxy for matrix disorganization. No validated peptide-specific response threshold for rotator cuff ultrasound exists yet.

Regulatory and Compounding Considerations

AOD-9604 is not approved by the FDA for any therapeutic indication. It is commercially available only through compounding pharmacies operating under state pharmacy board oversight, or through research-chemical suppliers. The FDA's 2023 guidance on peptides reclassified several compounds (including BPC-157) as Category 2 substances ineligible for compounding under Section 503A; AOD-9604 was not explicitly listed in that guidance as of mid-2025, but practitioners should verify current 503A/503B eligibility with their compounding pharmacy before prescribing [10].

Patients sourcing AOD-9604 from unregulated online vendors accept unknown purity, sterility, and peptide authenticity risks. A 2021 analysis of 44 commercially available peptide products found that only 68.2% contained the labeled peptide at the stated concentration, and 22.7% were contaminated with bacterial endotoxins [11].

Patient Selection: Who Is a Reasonable Candidate?

Good candidates share several features. They have radiologically confirmed tendinopathy (not a full-thickness tear or bony pathology). They have completed at least 12 weeks of guided physiotherapy without adequate response. They do not have active malignancy, are not pregnant or breastfeeding, and have no uncontrolled metabolic disease. They understand the investigational nature of the therapy and consent to monitoring.

Poor candidates include anyone who expects the peptide to substitute for rehabilitation, anyone with a fasting IGF-1 above the upper limit of the age-adjusted reference range before starting (suggesting pre-existing GH-axis excess), and anyone with a history of GH-sensitive neoplasms.

Expected Timeline of Outcomes

Tendon remodeling is slow. Patients should not expect pain reduction before week 6 to 8, and functional gains typically accumulate through week 12 to 16. This mirrors the natural history of GH-stimulated collagen synthesis: collagen type I production increases within days of stimulus, but fiber organization and tensile strength recovery take weeks to months.

A reasonable expectation framework for informed consent:

• Weeks 1 to 4. Little to no perceptible change. Injection tolerance is established.
• Weeks 4 to 8. Some patients report reduced morning stiffness and mild pain improvement. Ultrasound may show early reduction in tendon thickness.
• Weeks 8 to 16. Functional improvement, improved VISA scores, and echo-texture normalization are the target outcomes. Response is not universal.
• Post-cycle (weeks 16 to 24). Continued rehabilitation consolidates structural gains. A second cycle may be considered after a 4-week washout if partial response was achieved.

The 2019 NICE guideline on tendinopathy management states that "the majority of tendinopathies improve with conservative management over 3 to 6 months," which contextualizes the time horizon patients and clinicians are working within when adding any adjunct therapy [12].